# LeonaBio, Inc.: overview LONA · Nasdaq · CIK 1620463 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/lona.md) · [Financials](/companies/lona/financials.md) · [Filings](/companies/lona/filings.md) · [Insiders](/companies/lona/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(7.46)](/filings/0001193125-25-269544.md) | not reported | [(2.34)](/filings/0001193125-26-211898.md) | [(1.78)](/filings/0001193125-26-352243.md) | [(1.68)](/filings/0001193125-25-269544.md) | not reported | [(1.73)](/filings/0001193125-26-211898.md) | [(0.80)](/filings/0001193125-26-352243.md) | | Free cash flow | $m | [(23.0) d](/filings/0001193125-25-269544.md) | [(26.0) d](/filings/0001193125-26-134565.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.49)](/filings/0000950170-23-009498.md) | [(2.53)](/filings/0000950170-24-018787.md) | [(3.09)](/filings/0000950170-25-029069.md) | [(25.19)](/filings/0001193125-26-134565.md) | [(24.70)](/filings/0001193125-26-134565.md) | | Free cash flow | $m | [(44.7)](/filings/0000950170-23-009498.md) | [(73.6)](/filings/0000950170-24-018787.md) | [(101)](/filings/0000950170-25-029069.md) | [(97.2)](/filings/0001193125-26-134565.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lona/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-26 | [Portman David J.](/insiders/2126186.md) | 10% owner | Purchase (P) | 3,149,470 | $3,149.47 | $9.92bn | [Form 4](/filings/0002126186-26-000002.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $17.1m | 1,859,322 | | Unchanged | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $7.1m | 777,100 | | Added +49,619 | | [ACORN CAPITAL ADVISORS, LLC](/funds/2054410.md) | 2026-06-30 | $5.8m | 634,539 | | Unchanged | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $4.3m | 464,398 | | Unchanged | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $4.3m | 464,398 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $4.3m | 464,398 | | Unchanged | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $3.6m | 393,701 | | Unchanged | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $3.6m | 393,701 | | Unchanged | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $3.6m | 393,701 | | Unchanged | | [Blackstone Inc.](/funds/1393818.md) | 2026-06-30 | $3.0m | 324,638 | | New +324,638 | ## Recent filings [All 466 filings](/companies/lona/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 15:37 ET | [SCHEDULE 13D/A](/filings/0001655566-26-000004.md) | Ownership report, active investor, amended | 0001655566-26-000004 | | 2026-10-26 | 16:00 ET | [SCHEDULE 13D/A](/filings/0001193125-26-431897.md) | Ownership report, active investor, amended | 0001193125-26-431897 | | 2026-09-22 | 16:20 ET | [8-K](/filings/0001193125-26-397952.md) | 8.01 Other events | 0001193125-26-397952 | | 2026-08-31 | 16:31 ET | [SCHEDULE 13D](/filings/0001655566-26-000003.md) | Ownership report, active investor | 0001655566-26-000003 | | 2026-08-26 | 16:05 ET | [8-K](/filings/0001193125-26-368288.md) | 8.01 Other events | 0001193125-26-368288 | | 2026-08-25 | 16:00 ET | [SCHEDULE 13D/A](/filings/0001193125-26-365096.md) | Ownership report, active investor, amended | 0001193125-26-365096 | | 2026-08-14 | 16:10 ET | [10-Q](/filings/0001193125-26-352243.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352243 | | 2026-08-14 | 16:07 ET | [8-K](/filings/0001193125-26-352208.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-352208 | | 2026-06-23 | 16:05 ET | [8-K](/filings/0001193125-26-279425.md) | 5.07 Shareholder vote results | 0001193125-26-279425 | | 2026-05-11 | 16:45 ET | [DEF 14A](/filings/0001193125-26-216742.md) | Proxy statement, period 2026-06-22 | 0001193125-26-216742 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134565.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1620463 - Tickers: LONA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:30 ET. No prices; not investment advice.